Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

Peckham, Merry; Spencer, Horace J.; Syed, Summer; Armstrong, William B.; Farwell, D. Gregory; Gal, Thomas J.; Goldenberg, David; Russell, Marika D.; Solis, Roberto N.; King, Deanne; Stack, Brendan C.

doi:10.1002/jso.26825

Cited by 3 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking the IVW fixed effects model as an example, our MR OR value (1.9146, 95% CI: 1.0147–3.6127) undoubtedly coincides with this finding. In a multicenter study conducted this year, the presence or absence of BN was not linked to the presence or absence of TN ( 22 ). These observational research results are contradictory and are difficult to prove.…”

Section: Discussionmentioning

confidence: 99%

Assessing the causality between thyroid and breast neoplasms: A bidirectional Mendelian randomization study

Xia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

AimThis study aimed to evaluate the association between thyroid neoplasms (TN) and the risk of developing breast neoplasms (BN) by assessing data on single nucleotide polymorphisms (SNPs) obtained from the Deutsches Krebsforschungszentrum (DKFZ) and Breast Cancer Association (BCAC).MethodsData on SNPs associated with TN and BN were obtained from DKFZ and BCAC, respectively. Secondary data analysis of all pooled data from genome-wide association studies (GWAS) was performed to identify the genetic loci closely associated with TN or BN as instrumental variables (IVs). To evaluate the causal relationship between TN and BN, a bidirectional Mendelian randomization (MR) analysis was performed using MR Egger regression, weighted median, inverse variance weighted (IVW) random effects model, simple mode, weighted mode, maximum likelihood, penalized weighted median, IVW radial, IVW fixed effects, and robust adjusted profile scores (RAPS) method.ResultsThe MR in this study demonstrated a modest reverse causal relationship between TN and BN but a significant positive causal relationship between BN and TN.ConclusionsThe MR of this study provided genetic evidence suggesting an association between BN and TN; however, further research is warranted to explore the potential mechanism of interaction between these two malignancies. Moreover, general breast screening should be performed in individuals with TN, but TN screening should be reinforced in individuals with BN.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessing the causality between thyroid and breast neoplasms: A bidirectional Mendelian randomization study

Xia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…These clinical studies assess the safety and effectiveness of new medications, combinations of treatments, and therapy modalities. Enrolling in clinical trials provides patients with access to novel treatments that may result in better outcomes ( 38 ). A comprehensive approach to therapy is ensured by the collaboration of endocrinologists, surgeons, radiation oncologists, and medical oncologists in customizing treatment programs depending on the diagnosis of each patient ( 38 ).…”

Section: Overview Of Thyroid Cancermentioning

confidence: 99%

“…Enrolling in clinical trials provides patients with access to novel treatments that may result in better outcomes ( 38 ). A comprehensive approach to therapy is ensured by the collaboration of endocrinologists, surgeons, radiation oncologists, and medical oncologists in customizing treatment programs depending on the diagnosis of each patient ( 38 ). Tracking therapy response and identifying any recurrence signals requires routine monitoring with imaging scans, blood tests, and clinical evaluations ( 38 ).…”

Section: Overview Of Thyroid Cancermentioning

confidence: 99%

Advances in targeted therapy and biomarker research in thyroid cancer

Guo,

Sun,

Wei

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Driven by the intricacy of the illness and the need for individualized treatments, targeted therapy and biomarker research in thyroid cancer represent an important frontier in oncology. The variety of genetic changes associated with thyroid cancer demand more investigation to elucidate molecular details. This research is clinically significant since it can be used to develop customized treatment plans. A more focused approach is provided by targeted therapies, which target certain molecular targets such as mutant BRAF or RET proteins. This strategy minimizes collateral harm to healthy tissues and may also reduce adverse effects. Simultaneously, patient categorization based on molecular profiles is made possible by biomarker exploration, which allows for customized therapy regimens and maximizes therapeutic results. The benefits of targeted therapy and biomarker research go beyond their immediate clinical impact to encompass the whole cancer landscape. Comprehending the genetic underpinnings of thyroid cancer facilitates the creation of novel treatments that specifically target aberrant molecules. This advances the treatment of thyroid cancer and advances precision medicine, paving the way for the treatment of other cancers. Taken simply, more study on thyroid cancer is promising for better patient care. The concepts discovered during this investigation have the potential to completely transform the way that care is provided, bringing in a new era of personalized, precision medicine. This paradigm shift could improve the prognosis and quality of life for individuals with thyroid cancer and act as an inspiration for advances in other cancer types.

show abstract

“…However, the study was unable to fully exclude the possibility of a common etiology or the effects of treatment. In recent years, several studies have examined the risk of breast cancer in relation to thyroid cancer ( 17 – 19 ). The latest study on patients with differentiated thyroid cancer in children and young adults demonstrated a heightened risk of solid malignancies associated with radioactive iodine (RAI) treatment, with the risk of RAI-associated breast cancer being the most prominent after a 20-year follow-up ( 18 ).…”

Section: Introductionmentioning

confidence: 99%

“…The latest study on patients with differentiated thyroid cancer in children and young adults demonstrated a heightened risk of solid malignancies associated with radioactive iodine (RAI) treatment, with the risk of RAI-associated breast cancer being the most prominent after a 20-year follow-up ( 18 ). Conversely, a comprehensive analysis of the medical records of 4.24 million women did not identify a correlation between breast cancer survivors and the risk of thyroid cancer ( 19 ). Similarly, an earlier analysis involving ten thyroid cancer registries worldwide, including 6,449 patients treated with radioiodine for differentiated thyroid carcinoma and 1,116 controls, failed to reveal a substantial increase in the risk of breast cancer following radioiodine treatment.…”

Section: Introductionmentioning

confidence: 99%

Association between breast cancer and thyroid cancer risk: a two-sample Mendelian randomization study

et al. 2023

View full text Add to dashboard Cite

BackgroundBreast and thyroid cancer are increasingly prevalent, but it remains unclear whether the observed associations are due to heightened medical surveillance or intrinsic etiological factors. Observational studies are vulnerable to residual confounding, reverse causality, and bias, which can compromise causal inference. In this study, we employed a two-sample Mendelian randomization (MR) analysis to establish a causal link between breast cancer and heightened thyroid cancer risk.MethodsWe obtained the single nucleotide polymorphisms (SNPs) associated with breast cancer from a genome-wide association study (GWAS) conducted by the Breast Cancer Association Consortium (BCAC). The FinnGen consortium’s latest and largest accessible GWAS thyroid cancer data at the summary level. We performed four MR analyses, including the inverse-variance-weighted (IVW), weighted median, MR-Egger regression, and weighted mode, to evaluate the potential causal connection between genetically predicted breast cancer and higher risk for thyroid cancer. Sensitivity analysis, heterogeneity and pleiotropy tests were used to ensure the reliability of our findings.ResultsOur study revealed causal relationship between genetically predicted breast cancer and thyroid cancer (IVW method, odds ratio (OR) = 1.135, 95% confidence interval (CI): 1.006 to 1.279, P = 0.038). However, there was no causal association between genetically predicted triple-negative breast cancer and thyroid cancer (OR = 0.817, 95% CI: 0.610 to 1.095, P = 0.177). There was no directional pleiotropy or horizontal pleiotropy in the present study.ConclusionThis two-sample MR study supports a causal link between ER-positive breast cancer and heightened the risk of thyroid cancer. Our analysis did not reveal a direct correlation between triple-negative breast cancer and thyroid cancer.

show abstract

Breast and thyroid cancer: A multicenter study with Accrual to Clinical Trials Network

Cited by 3 publications

References 42 publications

Assessing the causality between thyroid and breast neoplasms: A bidirectional Mendelian randomization study

Assessing the causality between thyroid and breast neoplasms: A bidirectional Mendelian randomization study

Advances in targeted therapy and biomarker research in thyroid cancer

Association between breast cancer and thyroid cancer risk: a two-sample Mendelian randomization study

Contact Info

Product

Resources

About